Compare BLDR & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | VTRS |
|---|---|---|
| Founded | 1998 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 12.0B |
| IPO Year | 2005 | N/A |
| Metric | BLDR | VTRS |
|---|---|---|
| Price | $112.71 | $10.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 6 |
| Target Price | ★ $143.89 | $11.17 |
| AVG Volume (30 Days) | 2.4M | ★ 9.0M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 4.45% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $15,653,056,000.00 | $14,124,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.28 | $1.61 |
| P/E Ratio | $21.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $94.35 | $6.85 |
| 52 Week High | $187.22 | $13.25 |
| Indicator | BLDR | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 57.69 |
| Support Level | $109.75 | $10.49 |
| Resistance Level | $114.67 | $10.73 |
| Average True Range (ATR) | 4.16 | 0.25 |
| MACD | 2.15 | -0.00 |
| Stochastic Oscillator | 89.57 | 62.02 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.